PD-L1xVEGF Bispecific: 1st Global Data from BioNTech/BMS
BioNTech and BMS reveal promising first-in-human global data for their novel PD-L1xVEGF bispecific antibody, showing potential in treating advanced solid tumors.
BioNTech and BMS reveal promising first-in-human global data for their novel PD-L1xVEGF bispecific antibody, showing potential in treating advanced solid tumors.